Virtual Europe Discussion Group
The Virtual Europe Discussion Group provides opportunities for the broader community of industry, academic, and regulatory professionals to meet and share ideas and experiences. The group will discuss scientific challenges in the field of biopharmaceutical development and regulation with a focus on Europe.
The Virtual Europe Discussion Group goals include:
- Share learning across industry, academia, and health authorities across Europe, with a focus on speakers from across the region.
- Generate new scientific and technical insights and solutions for developing biopharmaceutical products in the future.
- Contribute to the expansion of CASSS’ mission, vision, influence, and community in Europe.
Click on the sections below for detailed information:
Critical Materials in Analytical Procedures | 13 November 2025 16:00 CEST | Virtual
Join peers across Europe for a virtual discussion on "From Vulnerability to Resilience: Industry Strategies for Dealing with Critical Materials in Analytical Procedures". The session will feature presentations from experts in the field, followed by an open discussion and Q&A. Come prepared to share questions and insights as we explore practical applications and emerging challenges together.
The Virtual Europe Discussion Group provides opportunities for the broader community of industry, academic, and regulatory professionals to meet and share ideas and experiences. Registration will open in October.
Attendance and Substitution Policy
CASSS reserves the right to withdraw, replace, add, or substitute presenters, speakers, and other guests without notice. Entry into the conference is at the sole discretion of CASSS and CASSS reserves the right to refuse entry to anyone for any reason.
Critical Materials in Analytical Procedures | 13 November 2025 16:00 CEST | Virtual
The pharmaceutical industry faces a variety of challenges that impact long-term robustness of analytical procedures used for quality control purposes. Challenges include supply chain fragility, quality variation of critical reagents or materials, or simply unexpected 'ghost peaks'. This discussion group explores strategic responses to such vulnerabilities, focusing on the transition from reactive troubleshooting to proactive resilience-building which starts already in the development labs. Using the recent Pharmalyte™️shortage as a case study, we examine how scientific understanding of the analytical methodology and collaborative efforts can catalyze industry-wide knowledge sharing and innovation. It is not sufficient to develop an analytical procedure that fulfills the 'analytical target profile' and that passes all validation criteria. The forward-looking method developer considers contingency planning, supplier diversification, and method adaptability to enhance analytical resilience during routine use of the method. We will discuss how structured troubleshooting can lead to methodological advancement and regulatory alignment.
Promote Your Participation
Here are some ways you can share your message:
- Follow CASSS on Facebook, X, and LinkedIn. Stay up-to-date on the latest Discussion Group announcements and opportunities. Links can be found in the right column or at the bottom of this page.
- Share your participation via your personal Facebook, X, and LinkedIn accounts. Whether you are a recurring presenter or this is your first time attending, we are grateful to have you join us this year.
- Share the news with your colleagues who run your organization's official social media channels. We are proud to show our community your participation - let your community convey their support too.
- Personalize your email signature. Add an image or short message to your default email signature to let your colleagues know you will be attending the Discussion Group.
- Remember to tag CASSS on all social media posts.
If you have any questions about this media kit, please reach out to Renee Olson.
